The updated guidance for people aged 16 and over recommends using smaller amounts of intravenous fluid initially for those at risk of serious illness or death due to sepsis. Patients should be ...

The government is backing groundbreaking research to detect bowel cancer earlier and more effectively. Recent investments include £2.4 million for an AI blood test that can spot cancer with over 99% ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

This guideline covers the recognition, diagnosis and early management of suspected sepsis in pregnant or recently pregnant people. It includes recommendations on recognition and early assessment, ...

There is a simple discount patient access scheme for garadacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in ...

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...

There is a simple discount patient access scheme for efanesoctocog alfa. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a simple discount patient access scheme for anhydrous sodium thiosulfate. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can ...

NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-mutated advanced non-small-cell lung cancer in adults after platinum-based chemotherapy. This is because ...

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...

Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. There is a simple discount patient ...